GRIN2D

Chr 19AD

glutamate ionotropic receptor NMDA type subunit 2D

Also known as: DEE46, EB11, EIEE46, GluN2D, NMDAR2D, NR2D

The protein forms part of NMDA receptor channels that are ionotropic glutamate receptors involved in synaptic transmission, learning, and memory. Loss-of-function mutations cause developmental and epileptic encephalopathy 46, inherited in an autosomal dominant pattern. The gene is highly intolerant to loss-of-function variants, indicating that haploinsufficiency disrupts normal NMDA receptor function critical for neuronal development and excitability.

GeneReviewsOMIMResearchSummary from RefSeq, OMIM, UniProt, Mechanism
GOFmechanismADLOEUF 0.171 OMIM phenotype
VCEP Guidelines: GRIN DisordersPilot
ClinGen Panel
Clinical SummaryGRIN2D
🧬
Gene-Disease Validity (ClinGen)
complex neurodevelopmental disorder · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
3 unique Pathogenic / Likely Pathogenic· 296 VUS of 500 total submissions
💊
Clinical Trials
1 active or recruiting trial — potential therapeutic options may be available
📖
GeneReview available — GRIN2D
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Dual constrained — LoF & missense intolerant
LoF Constraint
0.17LOEUF
pLI 1.000
Z-score 5.39
OE 0.05 (0.020.17)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint
4.85Z-score
OE missense 0.44 (0.400.49)
266 obs / 600.2 exp
Constrained

Highly missense-constrained (top ~0.1%)

Observed / Expected Ratios
LoF OE0.05 (0.020.17)
00.351.4
Missense OE0.44 (0.400.49)
00.61.4
Synonymous OE0.84
01.21.6
LoF obs/exp: 2 / 37.8Missense obs/exp: 266 / 600.2Syn Z: 2.11
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongGRIN2D-related severe epileptic encephalopathy treatable with NMDA receptor channel blockersGOFAD
DN
0.4983th %ile
GOF
0.6735th %ile
LOF
0.66top 25%

This gene has evidence for multiple mechanisms of pathogenicity (loss-of-function and gain-of-function). The Badonyi & Marsh model scores gain-of-function highest among its predictions, but genomic evidence (constraint, ClinVar variant spectrum, and literature) most strongly supports loss-of-function (haploinsufficiency). Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

LOFprediction above median · LOEUF 0.17
GOFprediction above median · 1 literature citation

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Literature Evidence

GOFOverall, these results suggest that NMDAR antagonists can be useful as adjuvant epilepsy therapy in individuals with GRIN2D gain-of-function mutations.PMID:27616483

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

ClinVar Variant Classifications

500 submitted variants in ClinVar

Classification Summary

Likely Pathogenic3
VUS296
Likely Benign185
Benign1
Conflicting4
3
Likely Pathogenic
296
VUS
185
Likely Benign
1
Benign
4
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
0
0
0
Likely Pathogenic
0
2
1
0
3
VUS
14
266
12
4
296
Likely Benign
0
4
31
150
185
Benign
0
0
1
0
1
Conflicting
4
Total1427245154489

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

GRIN2D · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold
Clinical Literature
Open Research Assistant →